Article
Oncology
Nicola J. Farrer, Geoff S. Higgins, Ian H. Kunkler
Summary: Combined chemoradiotherapy is the standard treatment for solid tumours, but systemic toxicity can limit chemotherapy delivery. Recent studies have shown that organic azides can be activated under radiation conditions, releasing drugs with reduced systemic toxicity. This approach may be relevant to glioblastoma and other solid tumours and offers potential for drug delivery from implanted devices.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Elizabeth B. B. Jeans, Daniel K. K. Ebner, Hirotoshi Takiyama, Kaitlin Qualls, Danielle A. A. Cunningham, Mark R. R. Waddle, Krishan R. R. Jethwa, William S. S. Harmsen, Joleen M. M. Hubbard, Eric J. J. Dozois, Kellie L. L. Mathis, Hiroshi Tsuji, Kenneth W. W. Merrell, Christopher L. L. Hallemeier, Anita Mahajan, Shigeru Yamada, Robert L. L. Foote, Michael G. G. Haddock
Summary: A comparative study between carbon-ion radiotherapy (CIRT) and multimodality therapy (CMT) for previously irradiated locally recurrent rectal cancer showed that CIRT has better overall survival rates at two and five years, equivalent local recurrence and disease progression rates, reduced treatment toxicity and lower patient cost. A prospective comparative study is needed to further evaluate the efficacy.
Review
Pharmacology & Pharmacy
Wei Wu, Jessica L. Klockow, Michael Zhang, Famyrah Lafortune, Edwin Chang, Linchun Jin, Yang Wu, Heike E. Daldrup-Link
Summary: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor with highly infiltrative nature and treatment resistance, highlighting the importance of innovative treatment strategies. The standard treatment for GBM is surgical resection followed by chemoradiotherapy, but the robust DNA repair and self-renewing capabilities of GBM cells lead to resistance against current therapies.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Oncology
Michelle Tseng, Natalie Y. L. Ngoi, David S. P. Tan, Pearl S. Y. Tong
Summary: The management of advanced cervical cancer has evolved over time, with combined modality treatment involving surgery, radiotherapy, and systemic therapy showing improved outcomes. This article reviews recent advances and international guidelines in the management of cervical cancer.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Sylvie Lorenzen, Michael Quante, Isabel Rauscher, Julia Slotta-Huspenina, Wilko Weichert, Marcus Feith, Helmut Friess, Stefanie E. Combs, Wolfgang A. Weber, Bernhard Haller, Martin Angele, Markus Albertsmeier, Christiane Blankenstein, Stefan Kasper, Roland M. Schmid, Florian Bassermann, Markus Schwaiger, Sven-Thorsten Liffers, Jens T. Siveke
Summary: This study aimed to differentiate responders and non-responders in patients with locally advanced gastroesophageal junction adenocarcinomas using PET scanning after induction chemotherapy. The primary objective was to improve the R0 resection rates in non-responders. The results showed that PET response was prognostic for overall survival and disease-free survival, but the goal of increasing R0 resection rates in non-responders was not achieved.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Yuedan Zhou, Sophie Espenel, Samir Achkar, Alexandra Leary, Sebastien Gouy, Cyrus Chargari
Summary: The standard treatment for locally advanced gynecological cancers is platinum-based concurrent chemoradiotherapy, but current chemotherapeutic drugs are only transiently effective and patients often develop resistance and distant metastases. This review discusses novel therapies that could work synergistically with conventional chemoradiotherapy, including anti-angiogenic agents, immunotherapy, tumor-infiltrating lymphocytes therapy, and apoptosis inducers. Radiosensitizers such as nanoparticles are also being tested to maximize the effect of radiotherapy locally.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Florian Amstutz, Silvia Fabiano, Louise Marc, Damien Charles Weber, Antony John Lomax, Jan Unkelbach, Ye Zhang
Summary: Optimally combined proton-photon plans have been shown to improve treatment plan quality compared to IMRT alone, potentially reducing the risk of toxicity while also allowing for increased accessibility to proton therapy for NSCLC patients.
Article
Medicine, General & Internal
Mu-Hung Tsai, Yung-Jen Cheng, Tzu-Hui Pao, Wei-Ting Hsueh, Helen H. W. Chen, Yuan-Hua Wu
Summary: This study compared the effectiveness of definitive chemoradiotherapy and upfront surgical treatment for advanced-stage oropharyngeal squamous cell carcinoma. The findings suggest that definitive chemoradiotherapy is comparable to upfront surgical treatment when adjusted for baseline factors associated with prognosis. Therefore, definitive chemoradiotherapy may be considered to avoid toxic effects associated with surgical treatment and chemoradiotherapy.
Article
Oncology
Verity Ahern, Sebastian Adeberg, Piero Fossati, Richard Garrett, Bradford Hoppe, Anita Mahajan, Ester Orlandi, Roberto Orecchia, Dale Prokopovich, Jan Seuntjens, David Thwaites, Daniel Trifiletti, Richard Tsang, Hiroshi Tsuji
Summary: This study aims to establish the treatment indications and potential patient numbers for carbon ion radiation therapy (CIRT) at a proposed national carbon ion (and proton) therapy facility in New South Wales, Australia. An expert panel, including representatives from operational and proposed international carbon ion facilities, as well as local stakeholders, met virtually to discuss the available evidence and experience. The study concluded that CIRT can be justified in Australia for certain tumor types, including adenoid cystic carcinomas, mucosal melanomas, hepatocellular cancer, liver metastases, base of skull meningiomas, chordomas, and chondrosarcomas. Approximately 1400 Australian patients annually meet the consensus-derived indications.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Hanguang Ruan, Masahiko Okamoto, Tatsuya Ohno, Yang Li, Yuan Zhou
Summary: Breast cancer is the most common malignant tumor in women, and radiotherapy is a common treatment. Although breast cancer radiotherapy technology has improved, complications should not be overlooked. Common complications include coronary toxicity, radiation pneumonia, and the risk of second primary cancer. Proton and carbon-ion radiotherapy have attracted interest as potential alternatives to conventional photon radiotherapy. This article summarizes clinical research on proton and carbon-ion radiotherapy for breast cancer treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Genetics & Heredity
Stefaan W. Van Gool, Jennifer Makalowski, Michael Bitar, Peter Van de Vliet, Volker Schirrmacher, Wilfried Stuecker
Summary: This study analyzed the prognosis of IDH1 wild-type MGMT promoter-unmethylated GBM patients and found that individualized multimodal immunotherapy may help improve the overall survival of patients. Retrospective analysis was performed on 32 patients who met the criteria, and the results showed that the extent of resection had a certain impact on the survival of patients.
GENES AND IMMUNITY
(2022)
Article
Oncology
Florian Amstutz, Reinhardt Krcek, Barbara Bachtiary, Damien C. Weber, Antony J. Lomax, Jan Unkelbach, Ye Zhang
Summary: This study investigates whether combined proton-photon therapy (CPPT) improves treatment plan quality compared to single-modality intensity-modulated radiation therapy (IMRT) or intensity-modulated proton therapy (IMPT) for head and neck cancer (HNC) patients. The findings suggest that CPPT needs adaptive treatments and increasing proton beam flexibility can improve treatment plan quality.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
L. Duenger, A. Seidlitz, C. Jentsch, I Platzek, J. Kotzerke, B. Beuthien-Baumann, M. Baumann, M. Krause, E. G. C. Troost, F. Raschke
Summary: The study aimed to evaluate changes in white matter mean diffusivity (MD) after radio(chemo)therapy in glioblastoma patients, comparing effects between proton and photon irradiation. Results showed that irradiation led to measurable MD reduction in white matter, progressing with increasing dose and time. Treatment with protons reduced this effect, indicating further investigations to correlate MD changes with radiation induced side-effects are needed.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Yi Lao, Victoria Yu, Anthony Pham, Theodore Wang, Jing Cui, Audrey Gallogly, Eric Chang, Zhaoyang Fan, Tania Kaprealian, Wensha Yang, Ke Sheng
Summary: Using a novel inverse distance map, the study found improved prediction of glioblastoma multiforme (GBM) recurrence and survival. Proximity scores (PS) based on the location of stem cell niches (SCNs) relative to tumors, with PSm-SCN being the strongest predictor for survival.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Review
Oncology
Ester Orlandi, Amelia Barcellini, Barbara Vischioni, Maria Rosaria Fiore, Viviana Vitolo, Alberto Iannalfi, Maria Bonora, Agnieszka Chalaszczyk, Rossana Ingargiola, Giulia Riva, Sara Ronchi, Francesca Valvo, Piero Fossati, Mario Ciocca, Alfredo Mirandola, Silvia Molinelli, Andrea Pella, Guido Baroni, Marco Giuseppe Pullia, Angelica Facoetti, Roberto Orecchia, Lisa Licitra, Gianluca Vago, Sandro Rossi
Summary: Carbon ion radiotherapy has advantages in rare, radioresistant, and difficult-to-treat tumors. CNAO has made significant contributions to the field and continuously improved its clinical, technical, and dosimetric skills.
Article
Oncology
Almut Dutz, Armin Luehr, Linda Agolli, Esther G. C. Troost, Mechthild Krause, Michael Baumann, Xavier Vermeren, Dirk Geismar, Emily F. Schapira, Meghan Bussiere, Jillian E. Daly, Marc R. Bussiere, Beate Timmermann, Helen A. Shih, Steffen Loeck
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Oncology
Michael Dworkin, William Mehan, Andrzej Niemierko, Sophia C. Kamran, Nayan Lamba, Jorg Dietrich, Maria Martinez-Lage, Kevin S. Oh, Tracy T. Batchelor, Patrick Y. Wen, Jay S. Loeffler, Helen A. Shih
JOURNAL OF NEURO-ONCOLOGY
(2019)
Article
Oncology
Devarati Mitra, Jeffrey W. Clark, Helen A. Shih, Kevin S. Oh, Priscilla K. Brastianos, Jennifer Y. Wo, Matthew R. Strickland, William T. Curry, Aparna R. Parikh, Ryan B. Corcoran, David P. Ryan, A. John Iafrate, Darrell R. Borger, Jochen K. Lennerz, Theodore S. Hong
Article
Oncology
Puyao C. Li, Norbert J. Liebsch, Andrzej Niemierko, Drosoula Giantsoudi, Simmons Lessell, Barbara C. Fullerton, Judith Adams, Helen A. Shih
RADIOTHERAPY AND ONCOLOGY
(2019)
Article
Oncology
Nayan Lamba, Marc R. Bussiere, Andrzej Niemierko, Parisa Abedi, Barbara C. Fullerton, Jay S. Loeffler, Kevin S. Oh, Lisa B. Nachtigall, Helen A. Shih
PRACTICAL RADIATION ONCOLOGY
(2019)
Article
Oncology
Sophia C. Kamran, Michael Dworkin, Andrzej Niemierko, Marc Bussiere, Kevin S. Oh, Jay S. Loeffler, Helen A. Shih
PRACTICAL RADIATION ONCOLOGY
(2019)
Article
Oncology
Shervin Tabrizi, Beow Y. Yeap, Janet C. Sherman, Lisa B. Nachtigall, Mary K. Colvin, Michael Dworkin, Barbara C. Fullerton, Juliane Daartz, Trevor J. Royce, Kevin S. Oh, Tracy T. Batchelor, William T. Curry, Jay S. Loeffler, Helen A. Shih
RADIOTHERAPY AND ONCOLOGY
(2019)
Review
Oncology
Susan G. R. McDuff, Jorg Dietrich, Katelyn M. Atkins, Kevin S. Oh, Jay S. Loeffler, Helen A. Shih
Article
Oncology
Grace Lee, Nayan Lamba, Andrzej Niemierko, Daniel W. Kim, Paul H. Chapman, Jay S. Loeffler, William T. Curry, Robert L. Martuza, Kevin S. Oh, Fred G. Barker, Helen A. Shih
Summary: The optimal timing of adjuvant radiation therapy in the management of atypical meningiomas remains controversial. Upfront adjuvant RT was associated with improved local control in atypical meningiomas irrespective of extent of initial resection compared with surveillance. Early adjuvant RT should be strongly considered after gross total resection of atypical meningiomas.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Letter
Oncology
Grace Lee, Nayan Lamba, Helen A. Shih
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Engineering, Biomedical
Nadya Shusharina, Jonas Soderberg, David Lidberg, Maximilian Niyazi, Helen A. Shih, Thomas Bortfeld
Summary: This paper addresses the issue of handling uncertainties in positions of anatomical barriers in defining the clinical target volume (CTV). An algorithm was developed to implement consensus guidelines by performing multiple expansions using the fast marching method with barriers in place or removed at different stages of the expansion. The algorithm was validated in a computational phantom, comparing manually generated with automated CTV contours while considering barrier uncertainties.
PHYSICS IN MEDICINE AND BIOLOGY
(2021)
Article
Oncology
Shivani Sud, Thomas Botticello, Andrzej Niemierko, Jillian Daly, Marc Bussiere, Helen A. Shih
Summary: This study compared the dosimetric differences between PSRS and XSRS for pituitary adenomas and found that both modalities showed comparable target volume dosimetry. However, PSRS offered lower maximum dose and EUD to critical proximal structures compared to XSRS, reducing the risk of radiation-induced secondary tumors by more than half.
ADVANCES IN RADIATION ONCOLOGY
(2021)
Editorial Material
Oncology
Helen A. Shih
PRACTICAL RADIATION ONCOLOGY
(2022)
Editorial Material
Oncology
Andrew B. Barbour, Lia M. Halasz
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Endocrinology & Metabolism
Amy J. Wisdom, M. Aiven Dyer, Nora K. Horick, Beow. Y. Yeap, Karen K. Miller, Brooke Swearingen, Jay S. Loeffler, Helen A. Shih
Summary: The purpose of this study was to investigate the impact of multidisciplinary treatment on the quality of life (QoL) of patients with nonfunctioning pituitary macroadenomas (NFPMA). The findings showed that radiation therapy after transsphenoidal surgery (TSS), hypopituitarism, and financial stressors were associated with impaired QoL in patients with NFPMA.